Tactile Systems Technology Inc
NASDAQ:TCMD
Tactile Systems Technology Inc
Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
Revenue Beat: Tactile Medical reported Q3 revenue of $85.8 million, up 17% year-over-year, driven by strong growth in both lymphedema and airway clearance products.
Guidance Raised: Full-year 2025 revenue guidance was increased to $317–321 million (8–10% growth YoY), and adjusted EBITDA guidance was also raised to $38–39.5 million.
Airway Clearance Growth: Airway clearance revenue surged 71% YoY, with AffloVest gaining market share and approaching market leadership.
Lymphedema Recovery: Lymphedema revenue rose 11% YoY and benefited from sales force expansion, CRM adoption, and a favorable Medicare policy shift.
Margin Improvement: Gross margin improved to 76% (up 80 bps YoY), and adjusted EBITDA grew 34% to $14.4 million.
Capital Allocation: Announced a new $25 million share repurchase program, reflecting strong free cash flow and confidence in business trajectory.
Strategic Execution: Continued investments in sales force, technology, and product innovation are beginning to deliver both top- and bottom-line results.
